WO2003020719A1 - 1,3-benzothiazinone derivatives and use thereof - Google Patents

1,3-benzothiazinone derivatives and use thereof Download PDF

Info

Publication number: WO2003020719A1
Authority: WO; WIPO (PCT)
Prior art keywords: diseases; optionally substituted; general formula; compounds; pirazinyl
Prior art date: 2001-09-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

PCT/JP2002/008866

Other languages

English (en)

French (fr)

Inventor

Masahiro Kajino

Akira Kawada

Yutaka Nakayama

Haruhide Kimura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-03

Filing date

2002-09-02

Publication date

2003-03-13

2002-09-02 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2002-09-02 Priority to EP02762953A priority Critical patent/EP1424336A4/en

2002-09-02 Priority to CA2459224A priority patent/CA2459224C/en

2002-09-02 Priority to US10/488,384 priority patent/US7399759B2/en

2003-03-13 Publication of WO2003020719A1 publication Critical patent/WO2003020719A1/ja

2004-03-03 Anticipated expiration legal-status Critical

2008-04-08 Priority to US12/099,779 priority patent/US7767665B2/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PCT/JP2002/008866 2001-09-03 2002-09-02 1,3-benzothiazinone derivatives and use thereof Ceased WO2003020719A1 (en)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
EP02762953A EP1424336A4 (en)	2001-09-03	2002-09-02	1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE
CA2459224A CA2459224C (en)	2001-09-03	2002-09-02	1,3-benzothiazinone derivatives and the use thereof
US10/488,384 US7399759B2 (en)	2001-09-03	2002-09-02	1, 3-benzothiazinone derivatives and use thereof
US12/099,779 US7767665B2 (en)	2001-09-03	2008-04-08	1,3-benzothiazinone derivatives and use thereof

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2001265743		2001-09-03
JP2001-265743		2001-09-03
JP2002180528		2002-06-20
JP2002-180528		2002-06-20

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
US10488384 A-371-Of-International		2002-09-02
US12/099,779 Continuation US7767665B2 (en)	2001-09-03	2008-04-08	1,3-benzothiazinone derivatives and use thereof

Publications (1)

Publication Number	Publication Date
WO2003020719A1 true WO2003020719A1 (en)	2003-03-13

Family

ID=26621530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/008866 Ceased WO2003020719A1 (en)	2001-09-03	2002-09-02	1,3-benzothiazinone derivatives and use thereof

Country Status (4)

Country	Link
US (2)	US7399759B2 (ja)
EP (1)	EP1424336A4 (ja)
CA (1)	CA2459224C (ja)
WO (1)	WO2003020719A1 (ja)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003086398A1 (en) *	2002-04-05	2003-10-23	Abbott Laboratories	Aminocarbonyl substituted pyridines, pyridazines, pyrimidines, pyrazines and triazines having antiangiogenic activity
WO2003090782A1 (en) *	2002-04-26	2003-11-06	Takeda Chemical Industries, Ltd.	Cell death inhibitor
WO2004060881A1 (ja) *	2002-12-05	2004-07-22	Takeda Pharmaceutical Company Limited	１，３−ベンゾチアジノン誘導体、その製造法および用途
WO2004096199A3 (en) *	2003-05-02	2006-03-30	Scottish Biomedical Ltd	Regulation of guanine nucleotide exchange factor
WO2006132438A1 (ja) *	2005-06-09	2006-12-14	Takeda Pharmaceutical Company Limited	１，３－ベンゾチアジノン誘導体およびその用途
JP2007534624A (ja) *	2003-07-16	2007-11-29	ニューロジェン・コーポレーション	ビアリールピペラジニル−ピリジン類縁体
WO2008035823A1 (en)	2006-09-22	2008-03-27	Takeda Pharmaceutical Company Limited	Cell death inhibitor
US7592466B2 (en)	2003-10-09	2009-09-22	Abbott Laboratories	Ureas having antiangiogenic activity
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9394285B2 (en)	2013-03-15	2016-07-19	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9540322B2 (en)	2008-08-18	2017-01-10	Yale University	MIF modulators
US9643922B2 (en)	2008-08-18	2017-05-09	Yale University	MIF modulators
US10011594B2 (en)	2015-06-03	2018-07-03	Bristol-Myers Squibb Company	4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
CN114957235A (zh) *	2021-05-27	2022-08-30	四川大学华西医院	苯并噻嗪酮衍生物及其制备方法和用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140679A (en)	2001-05-24	2010-01-15	Avanir Pharmaceuticals	Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
US7399759B2 (en) *	2001-09-03	2008-07-15	Takeda Pharmaceutical Company Limited	1, 3-benzothiazinone derivatives and use thereof
TW200418829A (en)	2003-02-14	2004-10-01	Avanir Pharmaceutics	Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
FR2881427A1 (fr) *	2005-01-31	2006-08-04	Oreal	Derives de 3-sulfanylpropanamide, composition les contenant et leur utilisation pour stimuler la pousse des cheveux et des cils et/ou freiner leur chute et/ou limiter leur depigmentation
WO2006102191A1 (en)	2005-03-24	2006-09-28	Avanir Pharmaceuticals	Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US20110082158A1 (en) *	2008-10-01	2011-04-07	Aleem Gangjee	Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
US8252804B2 (en) *	2008-10-01	2012-08-28	Duquesne University Of The Holy Spirit	Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
ES2462715T3 (es)	2008-12-19	2014-05-26	Genentech, Inc.	Compuestos y métodos de uso
IN2012DN02679A (ja)	2009-10-12	2015-09-04	Bayer Cropscience Ag
WO2015026851A1 (en) *	2013-08-20	2015-02-26	Olatec Industries Llc	Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate
US10336672B2 (en)	2014-08-04	2019-07-02	ClearWaterBay Technology, Inc.	System and method for producing neopentyl glycol
CN105384684B (zh) *	2015-12-16	2018-02-13	辽宁工程技术大学	一种2‑氰基‑6‑甲基吡啶的制备方法
EP4110765A4 (en) *	2020-02-28	2024-03-06	Board of Regents, The University of Texas System	RECEPTOR-INTERACTING PROTEIN KINASE I INHIBITORS FOR THE TREATMENT OF DISEASE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002018356A1 (en) *	2000-08-31	2002-03-07	Takeda Chemical Industries, Ltd.	Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399759B2 (en)	2001-09-03	2008-07-15	Takeda Pharmaceutical Company Limited	1, 3-benzothiazinone derivatives and use thereof
EP1500402A4 (en) *	2002-04-26	2009-12-30	Takeda Pharmaceutical	INHIBITOR OF CELL DEATH

2002
- 2002-09-02 US US10/488,384 patent/US7399759B2/en not_active Expired - Fee Related
- 2002-09-02 EP EP02762953A patent/EP1424336A4/en not_active Withdrawn
- 2002-09-02 WO PCT/JP2002/008866 patent/WO2003020719A1/ja not_active Ceased
- 2002-09-02 CA CA2459224A patent/CA2459224C/en not_active Expired - Fee Related
2008
- 2008-04-08 US US12/099,779 patent/US7767665B2/en not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002018356A1 (en) *	2000-08-31	2002-03-07	Takeda Chemical Industries, Ltd.	Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOLL. SCI. FAC. CHIM. IND., 1987, BOLOGNA, pages 37 - 39 *
CHEMICAL ABSTRACTS, vol. 51, Columbus, Ohio, US; abstract no. 17927G-H, XP002961051 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003086398A1 (en) *	2002-04-05	2003-10-23	Abbott Laboratories	Aminocarbonyl substituted pyridines, pyridazines, pyrimidines, pyrazines and triazines having antiangiogenic activity
WO2003090782A1 (en) *	2002-04-26	2003-11-06	Takeda Chemical Industries, Ltd.	Cell death inhibitor
US8173360B2 (en)	2002-04-26	2012-05-08	Takeda Pharmaceutical Company Limited	Cell death inhibitor
EP2270505A1 (en)	2002-04-26	2011-01-05	Takeda Pharmaceutical Company Limited	A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF)
US7659267B2 (en)	2002-12-05	2010-02-09	Takeda Pharmaceutical Company Limited	1,3-Benzothiazinone derivatives, process for producing the same use thereof
WO2004060881A1 (ja) *	2002-12-05	2004-07-22	Takeda Pharmaceutical Company Limited	１，３−ベンゾチアジノン誘導体、その製造法および用途
WO2004096199A3 (en) *	2003-05-02	2006-03-30	Scottish Biomedical Ltd	Regulation of guanine nucleotide exchange factor
JP2007534624A (ja) *	2003-07-16	2007-11-29	ニューロジェン・コーポレーション	ビアリールピペラジニル−ピリジン類縁体
US7592466B2 (en)	2003-10-09	2009-09-22	Abbott Laboratories	Ureas having antiangiogenic activity
WO2006132438A1 (ja) *	2005-06-09	2006-12-14	Takeda Pharmaceutical Company Limited	１，３－ベンゾチアジノン誘導体およびその用途
WO2008035823A1 (en)	2006-09-22	2008-03-27	Takeda Pharmaceutical Company Limited	Cell death inhibitor
JP5250419B2 (ja) *	2006-09-22	2013-07-31	武田薬品工業株式会社	細胞死抑制剤
US9044483B2 (en)	2006-09-22	2015-06-02	Takeda Pharmaceuticals Company Limited	Cell death inhibition by macrophage migration inhibitory factor and a binding substance thereto
US10202343B2 (en)	2008-08-18	2019-02-12	Yale University	MIF modulators
US9540322B2 (en)	2008-08-18	2017-01-10	Yale University	MIF modulators
US9643922B2 (en)	2008-08-18	2017-05-09	Yale University	MIF modulators
US11584717B2 (en)	2008-08-18	2023-02-21	Yale University	MIF modulators
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9394285B2 (en)	2013-03-15	2016-07-19	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US10336739B2 (en)	2015-06-03	2019-07-02	Bristol-Myers Squibb Company	4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
US10011594B2 (en)	2015-06-03	2018-07-03	Bristol-Myers Squibb Company	4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
CN114957235A (zh) *	2021-05-27	2022-08-30	四川大学华西医院	苯并噻嗪酮衍生物及其制备方法和用途
CN114957235B (zh) *	2021-05-27	2023-10-24	四川大学华西医院	苯并噻嗪酮衍生物及其制备方法和用途

Also Published As

Publication number	Publication date
US7767665B2 (en)	2010-08-03
CA2459224C (en)	2012-05-08
US20090082343A1 (en)	2009-03-26
EP1424336A1 (en)	2004-06-02
EP1424336A4 (en)	2004-11-10
US20050032786A1 (en)	2005-02-10
CA2459224A1 (en)	2003-03-13
US7399759B2 (en)	2008-07-15

Publication	Publication Date	Title
WO2003020719A1 (en)	2003-03-13	1,3-benzothiazinone derivatives and use thereof
WO2002018334A3 (en)	2002-06-13	Sodium channel modulators
NZ514095A (en)	2001-09-28	Amide compounds and medicinal use thereof
CY1120169T1 (el)	2018-12-12	Παραγωγο αμιδιου και φαρμακο
WO2004067550A3 (fr)	2004-10-14	Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
BR0309553A (pt)	2005-02-09	Composto ou sal farmaceuticamente aceitável ou éster ou amida hidrolisável in vivo deste, processo para prepará-lo, composição farmacêutica, uso do composto, e, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, e para tratar câncer em um animal de sangue quente
ATE202076T1 (de)	2001-06-15	Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
CA2413313A1 (en)	2002-12-20	Antitumor effect potentiators
EP1609798A4 (en)	2009-06-17	CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF
DK1213296T3 (da)	2004-08-16	Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
WO2005056524A3 (en)	2005-09-22	Therapeutic agents useful for treating pain
WO2003053368A3 (en)	2003-09-18	Chalcone derivatives and their use to treat diseases
WO2003080582A3 (de)	2004-12-09	Fredericamycin-derivate
BRPI0116967A2 (pt)	2009-07-14	derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste
CA2517933A1 (en)	2004-09-16	Novel fused heteroaromatic compounds as transforming growth factor (tgf) inhibitors
WO2004026306A3 (en)	2004-07-01	Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CA2369560A1 (en)	2000-11-02	Agent for prophylaxis and treatment of liver disease
WO2002100858A3 (en)	2003-02-20	Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
WO2000068198A3 (en)	2001-04-05	Heterosubstituted pyridine derivatives as pde 4 inhibitors
WO2002060386A3 (en)	2002-10-10	METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
WO2002085853A3 (en)	2002-12-19	Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2003051838A3 (en)	2003-09-18	Protein kinase inhibitors
AU4723197A (en)	1998-05-22	Tricyclic amine derivatives
CA2404594A1 (en)	2001-10-11	Agent for prophylaxis and treatment of renal disease
CA2347939A1 (en)	2000-05-04	Composition for the treatment of rheumatism, hepatitis or pancreatitis

Legal Events

Date	Code	Title	Description
2003-03-13	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM
2003-03-13	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG
2003-04-10	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-05-07	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-03-01	WWE	Wipo information: entry into national phase	Ref document number: 2459224 Country of ref document: CA
2004-03-02	REEP	Request for entry into the european phase	Ref document number: 2002762953 Country of ref document: EP
2004-03-02	WWE	Wipo information: entry into national phase	Ref document number: 2002762953 Country of ref document: EP
2004-06-02	WWP	Wipo information: published in national office	Ref document number: 2002762953 Country of ref document: EP
2004-09-13	WWE	Wipo information: entry into national phase	Ref document number: 10488384 Country of ref document: US
2004-12-14	NENP	Non-entry into the national phase	Ref country code: JP